EXPAND MY PIPELINE

Identifying hidden and novel targets helps us diversify and de-risk our pipeline.

Turbine's answer

Simulated modulation of undrugged targets in models that are inaccessible for conventional CRISPR or KD screens

Understanding the mechanisms behind response and resistance would help us select the preclinical programs in our pipeline with the greatest clinical upside.

Turbine's answer

Mechanistic explanation of effects of target perturbation at the protein and pathway activity level

Knowing the ‘right patient’ from the get-go will increase our clinical success rate and reduce our time to market.

Turbine's answer

Synthetic lethality screening for every target candidate to complement target ID with predictive biomarker hypotheses

BENEFITS ONLY TURBINE PROVIDES

Faster identification of novel targets, regardless of druggability or CRISPR-dependence

Causal hypotheses to enhance translatability of preclinical correlation to clinical efficacy

Turbine has the capacity to run drug modifier-like screens for every novel target candidate

Biomarker-driven target ID enhancing development potential and enabling target prioritization

1 month to train avatar

360

360M+ ideas explored

5 months to understand a complex biological mechanism and deliver ranked targets and validation workplans

Turbine has provided multiple targets that have first-in-class potential, along with the biology-driven insights necessary to rapidly validate this potential.

*Turbine Achieves Key Milestone in Collaboration with Ono